Codexis Reports 19% Revenue Growth, Cuts Net Loss by 33%, Boosted by $37.8M Merck Deal
CDXS sits 82% above its 52-week low of $0.958 on elevated volume (2.0× avg).
Summary
Codexis reported strong Q4 and fiscal year 2025 financial results, with full-year revenue increasing 19% to $70.4 million and a significant reduction in net loss to $44.0 million from $65.3 million in the prior year. The company also completed a material $37.8 million Technology Transfer Agreement with Merck in Q4 2025, which is a substantial positive for a company of its size. The improved profitability, higher gross margin of 64%, and a cash runway through 2027 demonstrate strong operational execution and commercial traction for Codexis's ECO Synthesis® Manufacturing Platform. Investors will be watching for progress on the GMP facility retrofit, expansion of CDMO partnerships, and the anticipated licensing deal with a major pharmaceutical company in the second half of 2026, which could further validate and monetize their technology.
At the time of this announcement, CDXS was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $114.7M. The 52-week trading range was $0.96 to $3.87. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.